Bile acid sequestrants The drugs of this group can interrupt the enterohepatic circulation of bile acids by binding to negatively charged bile acids and bile salts in the small intestine. This binding results in increasing the conversation of cholesterol into bile. Increased bile acids secretion resul...
Current Drug Treatment includes statins, bile acid sequestrants, ezetimibe that have side effects like rhabdomyolysis, muscle complaints, gastrointestinal disturbances, myalgia. Recent targets of the obesity are Amylin analogues, leptin analogues, GLP-1 analogues, Neuropeptide Y antagonists etc., which ...
Chapter 3 focused on a physicochemical study of the interaction between the bile acid sequestrants used in the treatment of hypercholesterolemia including colesevelam and cholestyramine with obeticolic acid (OCA), potent agonist of nuclear receptor farnesoid X (FXR). In particular, a new experimental...
Other therapies include bile acid sequestrants, niacin, and plant stanols. However, none of these is, in general, sufficiently effective as an initial agent to achieve these more aggressive LDL-C goals in the high-risk patient. However, combination therapy with a statin and 1 of these other...
Additional therapy with ezetimibe and bile acid sequestrants may be required. Newer classes of pharmacotherapy currently under investigation include lomitapide, mipomersen, and monoclonal antibodies to PCSK9. Lipoprotein apheresis may be required when multiple pharmacotherapies are inadequate, especially in ...
Bile acid sequestrants (BASs) are non-systemic therapeutic agents used for the management of hypercholesterolemia. They are generally safe and not associated with serious systemic adverse effects. Usually, BASs are cationic polymeric gels that have the ability to bind bile salts in the small ...